Login Contact Us
Jul 2024, Vol 12, Issue 3
Advanced Search
How do you find the scientific quality of the published articles on our web site?
Original Article
Therapeutic Effect of Bromocriptine as a Dopamine Agonist on Endometrioma Size: A Double-Blind Randomized Controlled Trial
Tahere Poordast1, Marziyeh Parizad Nasir Kandi2, Elnaz Hosseini Najarkolaei2, Elham Askari1, Azizeh Farshbaf Khalili3
1Infertility Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
2Laparoscopy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
3Physical Medicine and Rehabilitation Research Center, Aging Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran

DOI: 10.15296/ijwhr.2023.27
Viewed : 3045 times
Downloaded : 2312 times.

Keywords : Ovarian endometrioma, Dysmenorrhea, Dyspareunia, Pelvic pain, Bromocriptine
Full Text(PDF) | Related Articles
Objectives: This study aimed to assess the therapeutic effect of a dopamine agonist (bromocriptine) together with medroxyprogesterone for three months on ovarian endometrioma size.

Materials and Methods: In this double-blind randomized clinical trial, 60 women with clinical or ultrasonographic evidence of residual ovarian endometriomas were randomly assigned into two groups (n=30/each): the Bromo group received medroxyprogesterone (20 mg) and bromocriptine (1.25 mg) twice a day orally for three months and the placebo group received medroxyprogesterone (20 mg) and placebo twice a day orally for three months. Demographic characteristics, pre- and post-treatment endometrioma size, pelvic pain, dysmenorrhea, and dyspareunia were compared in both groups.

Results: Mean endometrioma size was significantly different in both groups compared with the pre-treatment stage (P < 0.0001). Endometriosis symptoms of dysmenorrhea, dyspareunia, and pelvic pain improved after the treatment in Bromo group compared with placebo group (P < 0.01).

Conclusions: We found that medroxyprogesterone with placebo is effective in reducing the ovarian endometrioma size and also improves dysmenorrhea, dyspareunia, and pelvic pain, but the combination of medroxyprogesterone and bromocriptine has a stronger effect than using medroxyprogesterone alone.

Cite By, Google Scholar

Google Scholar

Articles by Poordast T
Articles by Askari E
Articles by Farshbaf Khalili A


Articles by Tahere Poordast
Articles by Elham Askari

Submit Paper
Online Submission System
IJWHR ENDNOTE ® Style Tutorials Publication Charge Women's Reproductive Health Research Center About Journal
Publication Information
Published Article Statistics